A Handshake Across Continents — and the Broken Trust That Followed.

An American firm entered a pact to acquire an Indian pharmaceutical refinery. Then its partner began rewriting the rules — and time began to run out.

It was the kind of deal that looked, on paper, like a model of global partnership. In the autumn of 2025, Tonson International Inc., a Florida-based investment and finance company, entered a formal joint venture agreement with Coppercast Pharmaceutical India Private Limited, a Delhi-registered firm, to jointly pursue the acquisition of a pharmaceutical manufacturing facility somewhere on the Indian subcontinent. The venture was brokered in no small part by Dr. Rana, a well-connected intermediary whose role — bringing the two parties together and nurturing the relationship through its early stages — was described by those close to the matter as indispensable.

Mr. Pritpal Singh, a principal at Coppercast, shook hands — figuratively and formally — on a deal that divided responsibilities cleanly: Tonson would secure and deploy the financing to pursue and close the acquisition. Coppercast would contribute its local knowledge, its Indian operational footprint, and its regulatory relationships. The joint venture agreement was executed in November 2025, with a term running through November 2026. A ticking clock was embedded in every clause.

Today, that clock is still ticking. But the partnership appears to be unraveling — not because the opportunity has faded, but because, according to Tonson’s executives and legal advisers, Coppercast and Mr. Pritpal have repeatedly sought to alter the terms of an agreement they have already signed, introducing new demands, new conditions, and new delays at each turn — most recently over a matter as procedurally straightforward as an escrow arrangement.

Key Terms at IssueThe joint venture, executed November 2025 and expiring November 2026, designates Tonson International as the sole funding party for the acquisition, including all bid deposits, purchase price, and transaction costs. Coppercast bears no financial obligation. The two parties are required to act through a New York-based escrow agent — a law firm with offices in Mount Kisco, New York — to hold and disburse Tonson’s contributions in an orderly, transparent manner. CopperCast’s repeated resistance to executing this escrow agreement has stalled the transaction.

“In business, your signature is your bond,” said a senior executive at Tonson International, speaking with unusual candor. “We executed a joint venture agreement in good faith. We accepted our obligations — heavy obligations, frankly, since we are funding this entire acquisition. What we cannot accept is a partner that treats a signed agreement as a draft to be renegotiated the moment it becomes inconvenient for them.”

“What we cannot accept is a partner that treats a signed agreement as a draft to be renegotiated the moment it becomes inconvenient for them.”

— Senior executive, Tonson International Inc.

The flashpoint, at least in its most recent incarnation, is an escrow agreement. The arrangement, which would establish a segregated, New York-law-governed trust account managed by a reputable New York law firm as neutral escrow agent, was designed to hold Tonson’s funds — covering the bid deposit, the purchase price, and transaction costs — in a transparent and protected manner as the parties moved toward a formal bid submission. The escrow arrangement is not a novelty; it is standard practice in cross-border acquisitions of this scale and complexity. And yet, according to Tonson’s account, Coppercast and its associates have introduced repeated objections and demands for amendments — to an agreement that, by Tonson’s telling, had already reached an advanced and agreed state.

Time, in deals of this kind, is not merely money. It is oxygen. Every week spent renegotiating a procedural document is a week closer to the expiration of the joint venture agreement, a week during which the target facility may attract other bidders, a week in which lenders and consortium partners may grow cold. Tonson’s management has made this arithmetic explicit in recent communications.

“We have made clear to our counterparts in India — in writing and in person — that time is of the essence,” said a Tonson spokesman. “The escrow agreement is not a substantive renegotiation of the joint venture. It is a mechanism to protect everyone’s interests. The resistance to signing it is baffling to us, and frankly, it is alarming.”

— — —

Dr. Rana, who first introduced the parties and helped architect the joint venture, occupies a complicated position in the unfolding dispute. Those close to Tonson say he has been caught between his role as introducer — and the goodwill and credibility that role conferred on Coppercast — and his inability or unwillingness to bring his Indian counterparts into compliance with the terms he helped negotiate. His silence on the escalating escrow controversy has not gone unnoticed in Tampa.

“Dr. Rana brought this deal together,” acknowledged a Tonson adviser. “We respected that. We extended a great deal of trust on the strength of that relationship. But trust is not a substitute for performance. And right now, the performance on the Coppercast side has not met even the minimum threshold of what a signed agreement requires.”

The legal dimensions of the situation are not abstract. Tonson’s legal counsel — which, per the joint venture and escrow documentation, has engaged a New York law firm to serve as escrow agent and legal anchor for the transaction — has issued pointed internal assessments of the risk that CopperCast’s conduct poses to the viability of the deal.

“Changing the rules in the middle of the game is not a negotiating tactic. It is a breach of the fundamental covenant of good faith that underlies every commercial agreement.”

— Legal counsel, Tonson International Inc.

“What we are witnessing here,” said one attorney advising Tonson, declining to be identified by name owing to client confidentiality obligations, “is a pattern of conduct that, in any American or English commercial law jurisdiction, would raise serious questions about good faith performance. The joint venture agreement is executed. It is binding. Demanding material changes to the escrow mechanics — which are designed precisely to protect both parties — after the fact and under time pressure is not a negotiating tactic. It is a breach of the fundamental covenant of good faith that underlies every commercial agreement.”

The attorney added a sharper warning: “If this pattern continues, Tonson will have well-documented grounds to assert that Coppercast has repudiated its obligations. And under the governing law of the joint venture agreement, the consequences of repudiation are significant.”

— — —

From the outside, the dispute might appear to be a bureaucratic skirmish over paperwork. It is not. The escrow agreement sits at the operational heart of the transaction. Under the structure agreed between the parties, Tonson bears the entire financial burden of the acquisition — the bid deposit, the full purchase price, all due diligence and legal costs, all third-party contractor fees. Coppercast contributes no capital. In exchange for that financial weight, Tonson requires precisely the kind of procedural certainty that a properly executed escrow arrangement provides: transparency over where the funds go, who controls the disbursement triggers, and how disputes are resolved.

That Coppercast — which, again, bears no financial obligation under the agreed terms — would resist this structure has left Tonson’s team deeply unsettled. “If you are not putting in the money, why would you object to the mechanism that governs the money?” asked one Tonson executive. “The only explanation that makes sense to us is that someone on the Coppercast side wants to preserve optionality — to keep the terms fluid, to maintain leverage. And that is not what you do with a partner. That is what you do with an adversary.”

Attempts to reach Mr. Pritpal and representatives of Coppercast Pharmaceutical India Private Limited for comment were not successful at the time of publication.

— — —

The broader backdrop is one familiar to any practitioner of cross-border M&A: the structural asymmetry between a capital-rich Western partner and a locally entrenched counterpart in a high-growth emerging market. The Indian pharmaceutical manufacturing sector, valued in the hundreds of billions and growing, has attracted serious international capital in recent years. Acquiring a functioning refinery — with existing licenses, infrastructure, and regulatory approvals already in place — can compress years of development time and cost into a single transaction. The opportunity is real. The motivation for Tonson’s engagement is clear.

What is equally clear, to lawyers and deal practitioners who have reviewed the situation at this newspaper’s request, is that the conduct attributed to Coppercast and Mr. Pritpal is not merely commercially inconvenient. It speaks to a deeper question of character — the kind of question that, once raised, does not easily go away.

“Integrity in business is not a soft concept,” said one veteran M&A attorney with extensive cross-border experience. “It means you do what you said you would do. You honor the documents you signed. You do not wait until your partner has committed time and resources and then begin extracting new concessions. That is not how durable commercial relationships are built. And it is not how you build a reputation that survives a single transaction.”

“That is not how durable commercial relationships are built. And it is not how you build a reputation that survives a single transaction.”

— Veteran M&A attorney, commenting on the pattern of conduct

For Tonson, the path forward remains uncertain. The joint venture agreement does not expire until November 2026, but the window for submitting a competitive bid — and for funding that bid through a properly constituted escrow — is narrower. Tonson’s management has indicated, in the clearest possible terms, that it will not allow the transaction to be held hostage indefinitely.

“We came to this deal in good faith,” said Tonson’s chief executive, in a statement provided to The Times. “We signed documents. We engaged counsel. We assembled financing. We have done everything we committed to do. What we will not do is allow a partner who has accepted no financial risk — none — to dictate new terms to us on the eve of execution. We are prepared to protect our interests by every means available to us under the joint venture agreement and applicable law. We would strongly prefer, however, to complete this transaction as partners. The question of whether that remains possible rests entirely with Coppercast and Mr. Pritpal.”

It is a statement that reads less like an olive branch than a deadline. In the pharmaceutical corridors of West Delhi, and in the deal rooms of Tampa, Florida, that message is unlikely to have gone unnoticed.